How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices, but causing investors to re-write the rules for predicting successful commercial market entry as they look to the second half of 2020.

Factors that went largely unnoticed six months ago have become central to investor analyses, including the accessibility of a drug and how well the product, and the company manufacturing it, can fit a virtual launch model. ...